Vivalis and Kaketsuken extend research collaboration

The extended research license covers two new viruses one in the field of human disease, the other in the veterinary field.

Vivalis has already granted Kaketsuken rights to the EBx cell lines (avian embryonic derived stem cell lines) to evaluate Vivalis EBx platform for the production of Kaketsuken’s human and animal vaccines. Following this amendment, Kaketsuken’s will have the right to test an aggregate of seven viruses both in human and veterinary fields.

Franck Grimaud, CEO of Vivalis, said: “Vivalis is pleased to extend the agreement with Kaketsuken and to support Kaketsuken’s R&D efforts for the development of human and veterinary vaccines. Furthermore, it is a new proof that the EBx cell line is not limited to few applications, but can be applicable to a very large spectrum of vaccines.”